Serum bone metabolic marker affects the lumbar osteoarthritis in a japanese population study  by Chiba, D. et al.
Table 1
Comparison of demographic data, bone mineral density, the severity of lumbar
osteoarthritis, and serum bone metabolic markers between males and females
Total Male Female P-value
Age 54.4 ± 14.9 53.3 ± 15.3 55.2 ± 14.7 0.121
BMI 23.0 ± 3.3 23.7 ± 3.1 22.6 ± 3.3 <0.001*
BMD 2.6 ± 0.4 2.9 ± 0.4 2.5 ± 0.3 <0.001*
LOA 7.1 ± 4.4 7.7 ± 4.4 6.8 ± 4.4 0.006*
BAP 15.4 ± 11.8 15.8 ± 15.8 15.2 ± 8.2 0.770
NTx 18.7 ± 8.7 19.0 ± 10.7 18.5 ± 7.1 0.663
Pen 120.7 ± 54.8 132.7 ± 50.2 112.9 ± 56.2 <0.001*
BMD: bone mineral density (osteo-sono assessment index), LOA: the summation of
Kellgren-Lawerence grade in each intervertebral section (L1/5 to L5/S1) with lateral
X-ray image, BAP: bone alkaline phosphatase (mg/ml), NTx: N-telopeptide of type I
collagen (nMBCE/l), Pen: pentosidine (nmol/l)
* P<0.05, Mann-Whitney U test.
Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81A54smoker) and smoking intensity (in pack-years) were asked at baseline.
Radiographs and MRI ﬁlms of knees were acquired at baseline and 30-,
60-, and 84-month visits. Kellgren& Lawrence (KL) gradewas scored on
posteroanterior knee radiographs and patellofemoral radiographic OA
was scored on lateral view knee radiographs. A knee was considered as
having whole knee radiographic OA (ROA) at baseline if it had either KL
grade 2 or patellofemoral ROA. Incident whole knee ROA was deﬁned
among knees without whole knee ROA at baseline if the disease
developed or new knee replacement surgery occurred during 84
months of follow-up. Cartilage morphology (CM) was scored on MRIs of
one knee per subject using the Whole Organ Magnetic Resonance Score
(WORMS). Cartilage lesions at baseline in the whole knee were deﬁned
as (1) any CM lesion: WORMS score 2 in any subregion, and (2) full
thickness CM lesion: WORMS score 2.5 or 5 in any subregion. CM
progression from baseline to 84-month visit was deﬁned as at least a
within-grade increase of WORMS score in any subregion. We examined
the relation of smoking status and intensity to prevalent whole knee
ROA at baseline with logistic regression, using generalized estimation
equations to account for the correlation between two knees within a
subject. We used the same approach to assess the effect of smoking on
incident whole knee ROA. We used logistic regression to assess the
relation of smoking to cartilage outcomes. The analysis of the relation of
smoking to CM progression was repeated among knees without whole
knee ROA at baseline. Baseline age, sex, race, clinic site, BMI, knee injury
and surgery histories were adjusted for in all models.
Results: Among 3026 subjects recruited at baseline (age mean ±; SD:
62.5 ±; 8.1, BMI mean ±; SD: 30.7 ±; 6.0 kg/m2, 60% women), 197
subjects (6.5%) were current smokers and 1155 (38.2%) were former
smokers. The median (25th, 75th percentile) smoking intensity among
smokers was 21.5 (15.0, 31.0) pack-years. The prevalence of whole knee
ROA at baseline was 46%, 43%, 45% among never, current, and former
smokers, respectively, and risks of incident whole knee ROA during 84-
month follow-up were 25%, 23%, and 24%. There was no signiﬁcant
relation of smoking to prevalent and incident whole knee ROA,
respectively (see table). Complete baseline CM scores were available
among 1006 knees (age mean ±; SD: 60.9 ±; 7.5, BMI mean ±; SD: 29.4
±; 4.6 kg/m2, 62% women). The prevalence of any CM lesion at baseline
was 71% among never smokers, and was not higher among current or
former smokers with odds ratios (95% CI) 1.1 (0.5, 2.2) and 0.9 (0.7, 1.2),
respectively (table). Similar results were found for the association
between smoking and prevalence of full thickness cartilage lesion at
baseline, as well as of CM progression. When limited to knees without
whole knee ROA at baseline, the odds ratios (95% CI) of CM progression
were 1.1 (0.5, 2.1) among current smokers and 1.0 (0.7, 1.3) among
former smokers compared with never smokers. No relation was found
between smoking intensity and radiographic OA outcomes as well as
cartilage outcomes (table).
Conclusions: Smoking was not related to radiographic knee OA or to
cartilage lesions in this community-based cohort of older adults.
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NOVEL METABOLIC MARKERS FOR CONCURRENCE OF
OSTEOARTHRITIS AND DIABETES MELLITUS IDENTIFIED BY A
METABOLOMICS APPROACH
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Purpose: Our previous study found that osteoarthritis (OA) consisted of
metabolically distinct subgroups andoneof the subgroups tended tohave
a high prevalence of metabolic diseases (BMJ Open 2014). The purpose of
the current studywas to identify novelmarkers for concurrence ofOA and
metabolic diseases by using a metabolomics approach.
Methods: Synovial ﬂuid and plasma samples were collected from
patients undergoing total knee joint replacements due to primary OA.
Plasma samples of healthy controls were also collected. Medical infor-
mation on hypertension, dyslipidemia, high-BMI and diabetes were
obtained by self-administered questionnaires and conﬁrmed by their
medical records. Metabolic proﬁling was performed on all the collected
samples using UPLC-MS coupled with mixed standards assay kits to
identify novel markers for OA and concurrence of OA and metabolic
diseases.
Results: 64 OA patients and 45 healthy people were included in the
study. Mean age were 65.6 ± 7.0 and 48.6± 6.3 years, respectively, and
the mean BMI were 33.9 ± 7.3 and 30.1±6.7 kg/m2, respectively. 168metabolite concentrations, including 40 acylcarnitines (including free
carnitine), 20 amino acids, 9 biogenic amines, 87 glycerophospholipids,
11 sphingolipids and 1 hexose (>90% glucose), were quantiﬁed sepa-
rately in synovial ﬂuid and plasma samples. OPLS-DA analysis showed
that diabetes OA patients could be clearly separated from non-diabetes
OA patients based on synovial metabolite concentrations. Similar pat-
tern was seen when plasma metabolite concentrations were used. 13
differential metabolites were identiﬁed between diabetes and non-
diabetes OA patients from synovial analysis, of which 11 metabolites
were the same as the differential metabolites identiﬁed in plasma
analysis. The comparisons of these 11metabolite plasma concentrations
between diabetes OA, non-diabetes OA, and healthy controls found that
5 metabolic markers, citrulline, arginine, leucine, PC ae C34:3 and PC ae
C36:3, were statistically and signiﬁcantly different between these three
groups with a linear trend (all p <0.003). Leucine has been associated
with knee OA in our previous study (ARD 2010). In addition, 3 metab-
olite concentrations, proline, alanine and acetyornithine, were stat-
istically different between diabetes OA patients and healthy controls (p
< 0.0001).
Conclusions: We conﬁrmed our previous ﬁndings and further identi-
ﬁed 7 novel metabolic markers for OA and concurrence of OA and
diabetes mellitus, suggesting OAmay have different pathogenesis when
concurring with diabetes mellitus.
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Purpose: To clarify the relationship between bone metabolic meas-
urements (bone mineral density: BMD, serum biomarker) and the
severity of lumbar osteoarthritis (LOA)
Methods: 689 volunteers participated in the present study (Male:
272, Female: 417, Age: 54.4±14.9, BMI: 23.0±3.3kg/m2). Lateral
lumbar radiographs were evaluated in each intervertebral section
(L1/2 to L5/S1) by Kellgren-Lawrence grade (KLG). If at least one
intervertebral section was determined as KLG 2 or more severe, the
subjects were deﬁned as LOA. The summation of each section was
determined as the severity score of LOA. BMD was evaluated by
osteo-sono assessment index at the calcaneus bone. Blood samples
were taken in early morning before breakfast. Serum bone alkaline
phosphatase (BAP; mg/ml), N-telopeptide of typeI collagen (NTx;
nMBCE/l), and pentosidine (Pen; nmol/l) were examined as the index
of bone metabolism. Multiple linear regression analysis was con-
ducted with the severity score of LOA as an independent variable, and
age, sex, BMI, BMD, and the value of serum samples (BAP, NTx, Pen) as
dependent variables.
Results: The total number of LOA subjects was 474 (68.5%). The
frequency of LOA in males (n¼199, 73.2%) was higher than that of
females (n¼273, 65.5%; P¼0.036, c2 test). The mean severity score of
LOA was 7.1±4.4 in total subjects, 7.8±4.4 in male, and 6.8±4.4 in
female (P¼0.006, Mann-Whitney U test). The mean value of BMD was
2.7±0.4106 in total subjects, 2.9±0.4106 in male, and 2.5±0.3106
in female (P<0.001, Mann-Whitney U test). The mean value of BAP
Table 2
Comparison of demographic data, bone mineral density, serum bone metabolic markers with and without lumbar osteoarthritis in each gender
Male Female
OA OA þ P OA OA þ P
Age 40.5 ± 13.0 58.0 ± 13.2 <0.001* 44.8 ± 12.7 60.7 ± 12.5 <0.001*
BMI 23.4 ± 3.8 23.8 ± 2.8 0.065 21.6 ± 2.7 23.1 ± 3.5 <0.001*
BMD 3.0 ± 0.5 2.8 ± 0.4 0.151 2.6 ± 0.3 2.4 ± 0.3 <0.001*
BAP 18.7 ± 29.2 14.7 ± 5.1 0.496 13.3 ± 6.2 16.2 ± 8.9 <0.001*
NTx 21.7 ± 19.0 18.0 ± 4.5 0.085 17.8 ± 7.0 18.9 ± 7.1 0.044*
Pen 120.71 ± 34.5 137.1 ± 54.3 0.016* 106.31 ± 30.5 116.41 ± 65.6 0.164
If at least one intervertebral section is determined as Kellgren-Lawrence grade 2 or more severe, the subjects are deﬁned as OAþ. BMD: bone mineral density (osteo-sono
assessment index), BAP: bone alkaline phosphatase (mg/ml), NTx: N-telopeptide of type I collagen (nMBCE/l), Pen: pentosidine (nmol/l)
*P<0.05, Mann-Whitney U test
Figure-1. Site-speciﬁc change in cartilage defects over 10 years.
Figure-2A. Site speciﬁc change in mean cartilage defects score in off-
spring and controls over 10 years. Figure-2B: Site speciﬁc incident of
cartilage defects in offspring and controls over 10 years (participants
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female. The mean value of NTx was 18.7±8.7 in total subjects,
19.0±10.7 in male, and 18.5±7.1 in female. The mean value of Pen was
120.7±54.8 in total subjects, 132.7±50.2 in male, and 112.9±56.2 in
female (P<0.001, Mann-Whitney U test, Table 1). In addition, the
mean value of age, BMI, BMD, BAP, NTx, and Pen was signiﬁcantly
different with and without LOA in each gender (Table 2). In multiple
regression model, age (b¼0.600, P<0.001), sex (male¼1, female¼2;
b¼0.136, P<0.001), BMI (b¼0.148, P<0.001), BAP (b¼0.101,
P¼0.025), and Pen (b¼0.120, P<0.001) signiﬁcantly affected the
severity score of LOA in a total population. Only age (b¼0.642,
P<0.001) and BMI (b¼0.155, P¼0.002) affected the severity score of
LOA in the male population, on the other hand, age (b¼0.568,
P<0.001), BMI (b¼0.138, P¼0.001), BAP (b¼0.174, P<0.001), and Pen
(b¼0.145, P<0.001) signiﬁcantly affected the severity score of LOA in
the female population.
Conclusions: The present study epidemiologically clariﬁed that serum
BAP and pentosidine levels positively correlated with the severity of
LOA in cross-sectional data. Pentosidine is one of the advanced glyca-
tion end products (AGEs). In in-vitro study, pentosidine was reported to
directly deteriorate the elastic property of collagen ﬁbers making the
cross-links, or indirectly degrade cartilage tissue affecting the speciﬁc
receptor for AGEs (RAGE) which induces several catabolic factors (ILs,
MMPs) via intracellular signal. Although serum pentosidine has been
established as the biomarker of bone quality, the utility for the bio-
marker of LOA needs to be paid attention longitudinally in the future.
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Purpose: Cartilage defects are a key structural abnormality in knee
osteoarthritis (OA) pathogenesis. However, there is limited long-term
data on the natural history of cartilage defects especially in early dis-
ease. The aim of this study was to describe the natural history of car-
tilage defects over 10 years, describe the predictors of change and
association with change in pain and structural co-pathologies.
Methods: 215 participants [mean age 45 (26-61); 58% female] were
studied at baseline, 2 and 10 years. Approximately half were the adult
offspring of subjects who had a knee replacement performed for knee
OA and the remaining half were randomly selected controls without a
family history of OA. Cartilage defects (tibiofemoral and patellar) were
evaluated, using T-1 weighted fat saturated gradient echo MRI, on a 0-4
scale. Cartilage volume, bone marrow lesions (BMLs), meniscal tears/
extrusion and effusion were assessed on (T-1 or T-2 weighted) MRI and
joint space narrowing (JSN) and osteophytes on radiographs using
standard protocols. Pain was assessed using Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC). Multivariable
analyses were adjusted for demographics, family history of OA, history
of knee injury and all the structural abnormalities assessed on radio-
graphs/MRI.
Results: 44% of the participants had at least one cartilage defect at any
site at baseline. Most of these defects remained stable, whereas 26%without any cartilage defects at baseline).
